Table 1.
Demographic data and clinical characteristics | MGUS (n = 86 ) | SMM1 (n = 25 ) | p < 2 | MM (n = 53 ) | p < 3 | |
---|---|---|---|---|---|---|
Sex: Female/Male (% Females) | 42/44 (48,8%) | 17/8 (68.0%) | 27/26 (50.9%) | |||
Age: years (Mean ± SEM ) | 67.0 ± 1.4 | 65.6 ± 2.9 | 68.4 ± 1.7 | |||
Risk and ISS stratification (n) 4 | 42 / 41 / 0 | 3 / 7 / 15 | 12 / 23 / 18 | |||
Monoclonal component | ||||||
Monoclonal component, g/dL (Mean ± SEM ) | 1.1 ± 0.1 | 1.6 ± 0.2 | 0.05 | 2.4 ± 0.3 | 0.001* | |
Bence Jones protein, no Yes/No (% Yes) | 10/62 (13.9%) | 11/12 (47.8%) | 0.001 | 34/12 (73.9%) | 0.001 | |
Immunoparesis, no Yes/No (% Yes) | 20/66 (23.3%) | 21/4 (84%) | 0.001 | 48/5 (90.6%) | 0.001 | |
Plasma cells (histology and immunophenotype) | ||||||
Histology-BMPC, % (Mean ± SEM ) | 3.96 ± 0.3 | 16.5 ± 2.6 | 0.001 | 33.9 ± 2.9 | 0.001* | |
Ratio aberrant/total-BMPC (Mean ± SEM ) | 73.1 ± 2.3 | 89.9 ± 4.1 | 0.001 | 96.0 ± 1.1 | 0.001 | |
Fluorescent in situ hybridization (FISH) | ||||||
p53 deletion, no Yes/No (% Yes) | 1/73 (1.3%) | 2/20 (9.1%) | 4/46 (8.0%) | |||
13q deletion, no Yes/No (%Yes) | 3/70 (4.1%) | 2/20 (9.1%) | 12/37 (24.5%) | 0.001 | ||
Break of IgH, no Yes/No (%Yes) | 2/73 (2.7%) | 4/18 (18.2%) | 0.05 | 9/38 (19.1%) | 0.01 | |
Aneuploidy, no Yes/No (% Yes) | 11/61 (15.3%) | 6/14 (30.0%) | 22/24 (57.8%) | 0.001 | ||
Any FISH alteration, no Yes/No (%Yes) | 15/61 (21.6%) | 13/8 (61.9%) | 0.001 | 34/14 (70.8%) | 0.001 |
Chr, Chromosome; SEM indicates standard error of mean;
Following new criteria of the Myeloma Working Group,32 20 out of 25 SMM should be included in the MM group.
Significant difference between MGUS and SMM (Pearson's χ2, Fisher's exact or Mann–Whitney tests).
Significant difference between MGUS and MM (Pearson's χ2, Fisher's exact or Mann–Whitney tests).
Risk factors (0/1/2 score) in MGUS and SMM, and international scoring system (ISS, I/II/III score) in MM. 33,34
Differences lower than p < 0.05 between SMM and MM.